Stephen J. Pettitt

Sutton Upon Derwent, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications

The PRECISE European initiative for cancer-vulnerability mapping and prediction.

The PRECISE European initiative for cancer-vulnerability mapping and prediction.

Journal: Nature genetics
Published: July 10, 2026

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Journal: JAMA oncology
Published: April 30, 2026

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

Journal: Molecular cancer therapeutics
Published: February 18, 2026

Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

Journal: British journal of cancer
Published: February 16, 2026

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Journal: NPJ precision oncology
Published: January 23, 2026

Mitotic single-stranded DNA suppression by DDIAS.

Mitotic single-stranded DNA suppression by DDIAS.

Journal: Molecular cell
Published: June 26, 2025

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Journal: Nature communications
Published: December 04, 2024

PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.

PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.

Journal: Oncogene
Published: June 17, 2024

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.

Journal: Cell reports. Medicine
Published: May 02, 2024

The transcriptomic architecture of common cancers reflects synthetic lethal interactions.

The transcriptomic architecture of common cancers reflects synthetic lethal interactions.

Journal: Nature genetics
Published: April 18, 2024

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.

Journal: bioRxiv : the preprint server for biology
Published: April 02, 2024

NASP modulates histone turnover to drive PARP inhibitor resistance.

NASP modulates histone turnover to drive PARP inhibitor resistance.

Journal: Nature
Published: April 02, 2024
Showing 1-12 of 64

Last Updated: 09/26/2026